User login
Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.
Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).
Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.
Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.
Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6
Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.
Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).
Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.
Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.
Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6
Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.
Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).
Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.
Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.
Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6